{"id":"358f2e8ac568","type":"article","url":"https://hartvaat.nl/2026/03/01/pravastatine-bij-volwassenen-met-adpkd-potentiele-subgroepvoordelen/","title":"Pravastatine bij volwassenen met ADPKD: potentiële subgroepvoordelen","title_en":"Reassessing pravastatin in adult autosomal dominant polycystic kidney disease and potential subgroup benefits","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":[],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01009-9/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01009-9/fulltext","authors":["Youyi Lu","Zhitao Teng","Zimin Meng"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":[],"congress":"","summary_en":"This commentary reassessed the evidence for pravastatin in autosomal dominant polycystic kidney disease, discussing potential subgroup benefits and the need for further study of statin effects on cyst growth and kidney function.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een reactie op de studie van Gitomer et al. over pravastatine bij autosomaal dominante polycystische nierziekte (ADPKD) bespreekt mogelijke voordelen in specifieke subgroepen. De auteurs pleiten voor een meer genuanceerde analyse van statinetherapie bij deze aandoening.","abstract_original":"We read with great interest the article by Gitomer et al.1 Although we commend the authors for their rigorous investigation of pravastatin in adult autosomal dominant polycystic kidney disease, several aspects warrant further discussion."}